JP2024023212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023212A5 JP2024023212A5 JP2023187689A JP2023187689A JP2024023212A5 JP 2024023212 A5 JP2024023212 A5 JP 2024023212A5 JP 2023187689 A JP2023187689 A JP 2023187689A JP 2023187689 A JP2023187689 A JP 2023187689A JP 2024023212 A5 JP2024023212 A5 JP 2024023212A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- lif
- binding antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 20
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 19
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 229910052697 platinum Inorganic materials 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 4
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- 102000012745 Immunoglobulin Subunits Human genes 0.000 claims 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000037844 advanced solid tumor Diseases 0.000 claims 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229950007221 nedaplatin Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- -1 phenatriplatin Chemical compound 0.000 claims 1
- 229950005566 picoplatin Drugs 0.000 claims 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 1
- 229960005399 satraplatin Drugs 0.000 claims 1
- 190014017285 satraplatin Chemical compound 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229950002860 triplatin tetranitrate Drugs 0.000 claims 1
- 190014017283 triplatin tetranitrate Chemical compound 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382432 | 2018-06-18 | ||
| EP18382432.5 | 2018-06-18 | ||
| PCT/IB2019/000812 WO2019243900A2 (en) | 2018-06-18 | 2019-06-17 | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| JP2020570163A JP7379390B2 (ja) | 2018-06-18 | 2019-06-17 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570163A Division JP7379390B2 (ja) | 2018-06-18 | 2019-06-17 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023212A JP2024023212A (ja) | 2024-02-21 |
| JP2024023212A5 true JP2024023212A5 (enExample) | 2024-05-27 |
| JP7603772B2 JP7603772B2 (ja) | 2024-12-20 |
Family
ID=62837845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570163A Active JP7379390B2 (ja) | 2018-06-18 | 2019-06-17 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
| JP2023187689A Active JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570163A Active JP7379390B2 (ja) | 2018-06-18 | 2019-06-17 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210187106A1 (enExample) |
| EP (1) | EP3806899A2 (enExample) |
| JP (2) | JP7379390B2 (enExample) |
| KR (1) | KR20210022065A (enExample) |
| CN (1) | CN112955178B (enExample) |
| AU (2) | AU2019291307B2 (enExample) |
| CA (1) | CA3103369A1 (enExample) |
| EA (1) | EA202092964A1 (enExample) |
| IL (1) | IL279444A (enExample) |
| MA (1) | MA52300A (enExample) |
| SG (1) | SG11202012576QA (enExample) |
| WO (1) | WO2019243900A2 (enExample) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| AU2015314980A1 (en) * | 2014-09-10 | 2017-03-02 | The Regents Of The University Of California | Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies |
| WO2016168440A1 (en) | 2015-04-17 | 2016-10-20 | Morphotek, Inc. | Methods for treating lung cancer |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| AU2019269131B2 (en) * | 2018-05-14 | 2024-02-22 | Fundació Privada Institució Catalana De Recerca I Estudis Avançats | Antibodies against LIF and dosage forms thereof |
-
2019
- 2019-06-17 EA EA202092964A patent/EA202092964A1/ru unknown
- 2019-06-17 KR KR1020217001441A patent/KR20210022065A/ko not_active Ceased
- 2019-06-17 US US17/252,449 patent/US20210187106A1/en not_active Abandoned
- 2019-06-17 MA MA052300A patent/MA52300A/fr unknown
- 2019-06-17 SG SG11202012576QA patent/SG11202012576QA/en unknown
- 2019-06-17 AU AU2019291307A patent/AU2019291307B2/en active Active
- 2019-06-17 CA CA3103369A patent/CA3103369A1/en active Pending
- 2019-06-17 EP EP19782687.8A patent/EP3806899A2/en active Pending
- 2019-06-17 CN CN201980053679.1A patent/CN112955178B/zh active Active
- 2019-06-17 WO PCT/IB2019/000812 patent/WO2019243900A2/en not_active Ceased
- 2019-06-17 JP JP2020570163A patent/JP7379390B2/ja active Active
-
2020
- 2020-12-14 IL IL279444A patent/IL279444A/en unknown
-
2023
- 2023-11-01 JP JP2023187689A patent/JP7603772B2/ja active Active
-
2024
- 2024-07-01 AU AU2024204564A patent/AU2024204564A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111182919B (zh) | 抗cd137抗体 | |
| KR101933990B1 (ko) | 인간화 ｐａｎｈｅｒ 항체 조성물 | |
| JP2020011980A5 (enExample) | ||
| JP2008531576A5 (enExample) | ||
| JP2019519499A5 (enExample) | ||
| SI2719708T1 (en) | Material and methods for treating or preventing HER-3-related diseases | |
| JP2013510868A5 (enExample) | ||
| JP2022058802A5 (enExample) | ||
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| JP2019110906A5 (enExample) | ||
| JP2018508512A5 (enExample) | ||
| FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
| JP2020508317A5 (enExample) | ||
| JP2016516800A5 (enExample) | ||
| KR20140023921A (ko) | ＥｒｂＢ 경로 저해제들에 대한 저항성을 극복하는 방법 | |
| ME02296B (me) | Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensom | |
| IL276675B2 (en) | Anti-PD-1 antibodies and uses thereof | |
| JP2020522562A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JPWO2022270524A5 (enExample) | ||
| JP2020522512A5 (enExample) | ||
| CN112041346B (zh) | 用于与抗pd-1抗体组合的抗cd137抗体 | |
| JP2024023212A5 (enExample) | ||
| JP2024071393A5 (enExample) | ||
| Russell et al. | The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck |